Pharmafile Logo
Pharmafocus logo
Advanced Search

depression

Showing 15 posts of 52 posts found.

spravato

Janssen’s party drug-based nasal spray becomes first new FDA-approved depression treatment in 30 years

March 6, 2019
Research and Development, Sales and Marketing Janssen, Spravato, depression, esketamine, pharma

The field of depression therapy has seen its biggest leap forward in over three decades, the FDA approval of Janssen’s …

News
pharmafocus_march_2019_cover

Read the March 2019 issue of Pharmafocus online now!

February 26, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Drug pricing, HIV, Trump, WHO, brexit, depression, mental health, pharmacovigilance, rare disease

Just one month to go until Brexit here in the UK, and it’s still all to play for. After months …

News

Researchers activate gene to reverse depression in mice

February 18, 2019
Sales and Marketing SIRT1, depression, genetics, mental health

Scientists at the Medical College of Georgia at Augusta University were able to directly activate a gene associated with depression …

News
janssen_latest_logo_on_sign_closer

Janssen’s esketamine drug recommended by FDA panel for depression

February 13, 2019
Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …

News
maps-2018-01-boulder-staged-lana-marcela-bruce-bryce-img_20180128_135008_preview

Psychedelic therapy: A new approach to mental health

December 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing LSD, MDMA, controlled substances, depression, mental health, pharma, psychotherapy

In November 2018, a Phase 2 clinical trial found that 76% of patients who underwent MDMA-assisted psychotherapy no longer had …

Feature
shutterstock_159488225

GSK’s anti-seizure drug shows promise in early depression study

November 2, 2018
Medical Communications, Research and Development GSK, GlaxoSmithKline, Potiga, depression, pharma

Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications …

News
alk_logo_32_nodith

Committee advises against FDA approval of Alkermes’ novel depression drug

November 2, 2018
Medical Communications, Sales and Marketing Alkermes, FDA, depression, pharma

Alkermes has been knocked back with the disappointing, though not entirely unexpected, news that the FDA-appointed Psychopharmacologic Drugs Advisory Committee …

News
24327909026_6435de0904_z

Ketamine’s antidepressant effects may be linked to brain’s opioid system

September 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ketamine, antidepressant, depression, mental health, opioid

Ketamine’s antidepressant effect works through the activation of the brains opioid receptors, a new study published in The American Journal …

News
vagus_nerve_stimulation

Nerve stimulation treatments improve quality of life in depressed people, study shows

August 23, 2018
Research and Development VNS, depression, neuroscience, psychiatry, quality of life, vagus nerve stimulators

Nerve stimulation treatments can significantly improve depressed people’s quality of life, even in cases in which an individual continues to …

News
jj

J&J’s ketamine-based antidepressant showed mixed success at Phase 3

May 8, 2018
Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …

News
fda2outsideweb

Alkermes sent reeling as FDA refuses review of depression treatment

April 3, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Alkermes, FDA, depression, major depressive disorder, pharma

Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …

News
shutterstock_157775444

NICE recommends for online and mobile depression programme for trial on NHS

January 24, 2018
Research and Development Deprexis, NHS, NICE, app, depression, pharma

NICE has said that a new online and mobile app should be trialled on the NHS in the treatment of …

News

J&J’s predicted blockbuster depression posts P2 data

January 3, 2018
Research and Development Johnson & Johnson, biotech, depression, drugs, pharma, pharmaceutical

Johnson & Johnson has revealed Phase 2 data for its treatment for depression, esketamine, and the results are positive. The …

News
nhs_sign

NHS talking therapies for mental health hit a high with 1.4 million referrals

December 5, 2017
Manufacturing and Production, Medical Communications NHS, anxiety, depression, mental illness, pharma

New data has revealed that the number of UK patients seeking talking therapies on the NHS is on the rise, …

News
ketmine_injection_i

First large-scale study gives hope for ketamine as a depression therapy

May 3, 2017
Research and Development Ketamine, depression, mental health

While the development of truly innovative mental health therapies has ground to a halt somewhat, scientific research in the field …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023